UB Paderborn / Katalog / Suche / in CDI

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

Annals of oncology, 2014-02, Vol.25 (2), p.339-345

2014

Volltextzugriff (PDF)

The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer

Current medical research and opinion, 2016-07, Vol.32 (7), p.1217-1224

2016

Volltextzugriff (PDF)

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype

Annals of oncology, 2015-08, Vol.26 (8), p.1685-1691

2015

Volltextzugriff (PDF)

Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes)

Cancer research (Chicago, Ill.), 1993-06, Vol.53 (12), p.2796-2802

1993

Volltextzugriff (PDF)

Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations

Pediatric neurology, 2021-10, Vol.123, p.50-66

2021

Volltextzugriff (PDF)

Abstract S6-04: Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of 2485 patients from the ABCSG-8 and transATAC studies using the PAM50 risk of recurrence (ROR) score

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.S6-S6-04

2013

Volltextzugriff (PDF)

Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis

Journal of clinical oncology, 1999-10, Vol.17 (10), p.3110-3116

1999

Volltextzugriff (PDF)

Abstract P5-07-03: Prosigna® results impact on adjuvant decision making in early breast cancer (EBC): Final analysis of the prospective WSG study

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P5-P5-07-03

2016

Volltextzugriff (PDF)

Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference

Pediatric neurology, 2013-10, Vol.49 (4), p.255-265

2013

Volltextzugriff (PDF)

Analysis of Molecular Scores for the Prediction of Distant Recurrence According to Body Mass Index and Age at Baseline

Annals of oncology, 2014-05, Vol.25, p.i8-i8

2014

Volltextzugriff (PDF)

Predicting Risk for Late Metastasis: the PAM50 Risk of Recurrence (ROR) Score After 5 Years of Endocrine Therapy in Postmenopausal Women with Hr+ Early Breast Cancer: a Study On 1,478 Patients from the Abcsg-8 Trial

Annals of oncology, 2013-05, Vol.24, p.iii29

2013

Volltextzugriff (PDF)

PLCG2 associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations related to functional classes of genetic variants

Journal of allergy and clinical immunology, 2024-01, Vol.153 (1), p.230-242

2024

Volltextzugriff (PDF)

Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma

Analytical biochemistry, 1990-07, Vol.188 (1), p.65-71

1990

Volltextzugriff (PDF)

DNA binding of iproplatin and its divalent metabolite cis-dichloro-bis-isopropylamine platinum(II)

Cancer chemotherapy and pharmacology, 1990-01, Vol.27 (3), p.248-250

1990

Volltextzugriff (PDF)

Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR+ early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.506-506

2013

Volltextzugriff (PDF)

Studies on the human metabolism of iproplatin

Cancer chemotherapy and pharmacology, 1989, Vol.25 (1), p.10-14

1989

Volltextzugriff (PDF)

Predicting local recurrence using PAM50 in postmenopausal endocrine responsive breast cancer patients

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.1008-1008

2014

Volltextzugriff (PDF)

A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors

Molecular cancer therapeutics, 2005-06, Vol.4 (6), p.948-955

2005

Volltextzugriff (PDF)

Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4501-4501

2010

Volltextzugriff (PDF)

Uptake and metabolism of iproplatin in murine L1210 cells

Cancer chemotherapy and pharmacology, 1989, Vol.25 (1), p.15-18

1989

Volltextzugriff (PDF)

A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days

Cancer chemotherapy and pharmacology, 1989-03, Vol.23 (3), p.186-191

1989

Volltextzugriff (PDF)

Abstract P2-10-02: Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER+ early breast cancer (EBC): An ABCSG study

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P2-P2-10-02

2012

Volltextzugriff (PDF)

S4-5: Comparison of PAM50 Risk of Recurrence (ROR) Score with OncotypeDx and IHC4 for Predicting Residual Risk of RFS and Distant-(D)RFS after Endocrine Therapy: A TransATAC Study

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.S4-S4-5

2011

Volltextzugriff (PDF)

Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (CHIP) in patients with advanced cancer

Cancer chemotherapy and pharmacology, 1983-01, Vol.11 (1), p.23-28

1983

Volltextzugriff (PDF)

Identification of cis-dichloro-bis-isopropylamine platinum(II) as a major metabolite of iproplatin in humans

Cancer research (Chicago, Ill.), 1988-06, Vol.48 (12), p.3533-3536

1988

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype

Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes)

Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations

Abstract S6-04: Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of 2485 patients from the ABCSG-8 and transATAC studies using the PAM50 risk of recurrence (ROR) score

Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis

Abstract P5-07-03: Prosigna® results impact on adjuvant decision making in early breast cancer (EBC): Final analysis of the prospective WSG study

Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference

Analysis of Molecular Scores for the Prediction of Distant Recurrence According to Body Mass Index and Age at Baseline

Predicting Risk for Late Metastasis: the PAM50 Risk of Recurrence (ROR) Score After 5 Years of Endocrine Therapy in Postmenopausal Women with Hr+ Early Breast Cancer: a Study On 1,478 Patients from the Abcsg-8 Trial

PLCG2 associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations related to functional classes of genetic variants

Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma

DNA binding of iproplatin and its divalent metabolite cis-dichloro-bis-isopropylamine platinum(II)

Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR+ early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype

Studies on the human metabolism of iproplatin

Predicting local recurrence using PAM50 in postmenopausal endocrine responsive breast cancer patients

A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors

Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC)

Uptake and metabolism of iproplatin in murine L1210 cells

A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days

Abstract P2-10-02: Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER+ early breast cancer (EBC): An ABCSG study

S4-5: Comparison of PAM50 Risk of Recurrence (ROR) Score with OncotypeDx and IHC4 for Predicting Residual Risk of RFS and Distant-(D)RFS after Endocrine Therapy: A TransATAC Study

Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (CHIP) in patients with advanced cancer

Identification of cis-dichloro-bis-isopropylamine platinum(II) as a major metabolite of iproplatin in humans

Suchergebnisse filtern